Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2014, Article ID 949515, 4 pages
Case Report

Durable Hematological and Major Cytogenetic Response in a Patient with Isolated 20q Deletion Myelodysplastic Syndrome Treated with Lenalidomide

Bagi Jana,1,2,3 Anas Khanfar,1,2 and Mary Ninan1,2,3

1The University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555, USA
2Department of Internal Medicine, 301 University Boulevard, Galveston, TX 77555, USA
3Divisions of Hematology and Oncology, 301 University Boulevard, Galveston, TX 77555, USA

Received 10 December 2013; Accepted 31 December 2013; Published 12 February 2014

Academic Editors: K. Jamil and D. Yin

Copyright © 2014 Bagi Jana et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Myelodysplastic syndrome (MDS) is a clonal bone marrow disorder characterized by ineffective hematopoiesis. It is characterized by peripheral blood cytopenia and significant risk of progression to acute myeloid leukemia result. Deletion of the long arm of chromosome 20 (20q deletion) is present in 3–7% of patients with MDS. Lenalidomide is an immunomodulatory agent with antiangiogenic activity. It is FDA approved for the treatment of anemia in patients with low or int-1 risk MDS with chromosome 5q deletion with or without additional cytogenetic abnormalities. Study of lenalidomide in patients with MDS without 5q deletion but other karyotypic abnormalities demonstrated meaningful activity in transfusion dependent patients; however, response of patients with isolated 20q deletion to lenalidomide is not known. We are reporting a patient with 20q deletion MDS treated with lenalidomide after he failed to respond to azacytidine; to our knowledge this is the first report of a patient with isolated 20q deletion treated with lenalidomide.